News | Deep Vein Thrombosis (DVT) | July 07, 2017

ACCESS PTS Study Demonstrates Efficacy of Ekos Therapy for Post-Thrombotic Syndrome

Participants saw an average reduction of symptoms from severe down to borderline mild

ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome

July 7, 2017 — BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions, June 14-17 in New Orleans. The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with Ekos therapy. The ACCESS PTS protocol using Ekos therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life, according to the company.

The ACCESS PTS study is a multicenter prospective single-arm study of 73 patients with iliofemoral DVT, meeting eligibility including a Villalta Score of 8 or greater (Villalta Score measures the signs and symptoms of PTS), and who had failed three months of conservative therapy. Patients were treated with anticoagulation drugs followed by Ekos therapy with balloon dilatation.

The study met its primary efficacy endpoint and showed a significant improvement of Villalta Scores of 34 percent at 30 days across 77 limbs treated among the 73 patients with a p-value of <0.0001. On average, patients treated in the study experienced a symptom reduction from severe down to borderline mild. The study also showed a 21 percent improvement in patients’ quality of life. There was one bleeding incident and one pulmonary embolism (PE), meeting the study’s safety endpoint.

“ACCESS PTS demonstrates that Ekos therapy with balloon dilatation is effective and safe in reducing the signs and symptoms of post-thrombotic syndrome for patients suffering from chronic deep vein thrombosis, while improving their quality of life,” said lead investigator Mark Garcia, M.D., of Vascular & Interventional Associates of Delaware in Wilmington, Del. “EKOS therapy is a useful and important option for physicians treating debilitating chronic DVT and PTS.”

In addition to Garcia, the study’s authors include Keith Sterling, M.D., of Inova Alexandria Hospital, Alexandria, Va.; Michael Jaff, DO, of Newton-Wellesley Hospital, Boston; Kenneth Ouriel, M.D., of Syntactx; Susan Kahn, M.D., of Jewish General Hospital, Pelham, N.Y.; and Anthony Comerota, M.D., of Jobst Vascular Institute, Toledo, Ohio.

Watch the VIDEO: How the Ekos Thrombolytic Technology Works to Dissolve Clots."

Read the article “Ultrasound-assisted Catheter-directed Thrombolysis Reduces Treatment Risks for Pulmonary Emboli.”

For more information: www.btg-im.com

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.